… In a recent observational study (n = 82) bone loss after stopping denosumab after 8 years
was attenuated in the small number of patients (n = 17) who started osteoporosis medication, …

… (n = 27) or 2 additional 60 mg injections of denosumab (n = 30); both groups were
subsequently followed for a period of 24 months. At 24 months, BMD at the LS did not differ from …

… N Guañabens7, … N Migone8, … in the part of exon 1 encoding the signal peptide, and two
missense mutations in exon 1 and exon 2 at the N-terminus of the latency associated peptide. …

Uncertainty regarding the benefits of vertebroplasty (VP) for the treatment of acute osteoporotic
vertebral fractures has recently arisen. A prospective, controlled, randomized single‐…

BACKGROUND: Reduced bone mass predisposes patients to the development of vertebral
fractures. Measurement of bone mass by non-invasive methods is used to detect patients …

Camurati-Engelmann disease (CED; MIM 131300), or progressive diaphyseal dysplasia, is
a rare, sclerosing bone dysplasia inherited in an autosomal dominant manner. Recently, the …

The purpose of this study was to determine the prevalence of osteoporosis, to estimate the
bone turnover and hormonal status, and to identify the factors associated with bone disease …

After liver transplantation there is a high incidence of fractures, with important rates of bone
loss during the first months. However, the long-term evolution of bone mass and metabolism …

Data on treatment of glucocorticoid‐induced osteoporosis (GIO) in men are scarce. We
performed a randomized, open‐label trial in men who have taken glucocorticoids (GC) for ≥3 …

BACKGROUND: Since primary biliary cirrhosis (PBC) is usually diagnosed in postmenopausal
women with minor cholestasis, it has been questioned whether PBC itself represents a …